As an oncogene, Trop2 has been found to be up-regulated in various kinds of human cancers, including glioma, breast cancer, cervical cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and prostate cancer [9, 30–32]. Here, TACSTD2 is linked to prostate carcinoma.